Eurofins Viracor BioPharma is proud to announce that we are building a new, state-of-the art, 110,000 sq. ft. facility; nearly doubling our current footprint. Slated to open in Q1 of 2022, our new facility in Lenexa, KS (just 25 miles west of our HQs in Lee’s Summit, Mo.), exemplifies our continued commitment to business expansion, enabling us to better support our clients’ innovative drug development efforts.
While keeping our clients and employees needs top of mind, we based the location of the facility on many factors including an evaluation of existing building sites, implications of upgrades, proximity to Kansas City International Airport, the FedEx hub, a rich talent base to recruit from, housing, and restaurants, just to name a few.
Critical to our success, this new facility expansion stems from the January 2020 decision to formally separate the BioPharma business as a new legal entity, within Eurofins Viracor. As a standalone business, we are better able to dedicate resources to support our growing strategic client partnerships, helping advance new therapies and vaccines to market with optimal quality testing services and enhanced timeliness, across multiple phases of drug development. A strong pipeline of new projects for 2022 and beyond, combined with explosive growth within our organization, sets Eurofins Viracor BioPharma on a successful project delivery path for the future.
Eurofins Viracor BioPharma’s new facility is located at 18000 West 99th Street, Lenexa, KS 66219
For more information, please email ClinicalTrials@eurofins-viracor.com.